1,1-diphenylbut-3-en-2-one | 93021-71-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,1-diphenylbut-3-en-2-one
• 英文别名: Acryloyldiphenylmethane
• CAS: 93021-71-7
• 化学式: C₁₆H₁₄O
• 分子量: 222.287
• InChiKey: JOOFBXHKDLXZNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1,1-diphenylbut-3-en-2-one 在 哌啶 、 lithium aluminium tetrahydride 作用下， 生成 4-benzylsulfanyl-1,1-diphenyl-butan-2-ol
  参考文献：
  名称：

  Studies in Organic Sulfur Compounds. X.¹ The Scope of the Raney Nickel Desulfurization of Cyclic Hemithioketals (1,3-Oxathiolanes and 1,3-Oxathianes)²

  摘要：

  DOI：

  10.1021/ja01550a075
• 作为产物：
  描述：

  4-methyl-4-(3-oxo-4,4-diphenyl-butyl)-morpholinium; iodide 在 sodium hydroxide 作用下， 生成 1,1-diphenylbut-3-en-2-one
  参考文献：
  名称：

  240.合成止痛药和相关化合物。第四部分 苯基取代的丙酮的曼尼希碱

  摘要：

  DOI：

  10.1039/jr9520001321

文献信息

• PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME
  申请人：Mikoshiba Katsuhiko

  公开号：US20120277423A1

  公开（公告）日：2012-11-01

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R 1 is a substituted or unsubstituted aryl or heterocyclyl group, R 2 , R 3 , and R 4 are hydrogen atoms, n is 2, X is halogen, R 5 and R 6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R 5 and R 6 are not hydrogen atoms at the same time, or R 5 and R 6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及：一种具有转谷氨酰胺酶抑制活性的酮化合物，由下式1、2或3表示： 其中R1是取代或未取代的芳基或杂环基团，R2、R3和R4是氢原子，n是2，X是卤素，R5和R6独立地表示氢原子或取代或未取代的C1-C10烷基、芳基或芳烷基团，其中R5和R6不同时为氢原子，或者R5和R6可以共同形成含氮原子（N）的饱和或未饱和的、取代或未取代的杂环基团；包含该化合物的蛋白质交联抑制剂；以及包含该化合物或蛋白质交联抑制剂的用于预防或治疗由蛋白质交联引起的疾病的组合物。
• Microwave-Assisted, Rhodium(III)-Catalyzed N-Annulation Reactions of Aryl and α,β-Unsaturated Ketones with Alkynes
  作者：Hyejeong Lee、Yong-Kyun Sim、Jung-Woo Park、Chul-Ho Jun

  DOI：10.1002/chem.201302699

  日期：2014.1.3

  New RhIII‐catalyzed, one‐pot N‐annulation reactions of aryl and α,β‐unsaturated ketones with alkynes in the presence of ammonium acetate have been developed. Under microwave irradiation conditions, the processes lead to rapid formation of the respective isoquinoline and pyridine derivatives with efficiencies that are strongly dependent on the steric nature of the aryl ring and enone substituents. By

  在乙酸铵存在下，已开发出新的Rh III催化的芳基和α，β-不饱和酮与炔烃的一锅N环化反应。在微波辐射条件下，该方法导致各自异喹啉和吡啶衍生物的快速形成，其效率强烈地取决于芳基环和烯酮取代基的空间性质。通过采用该方案，可以高收率制备各种异喹啉和吡啶衍生物。此外，一种新的一锅法合成吡啶，涉及酮，甲醛，NH 4的四组分反应OAc和炔烃已被发现。该过程通过一条路线进行，该路线涉及酮与甲醛的初始醛醇缩合反应，生成支链的α，β-不饱和酮，然后将其用NH 4 OAc和炔烃进行Rh III催化的N环化。
• Inhibitor of protein crosslinking and use of the same
  申请人：Mikoshiba Katsuhiko

  公开号：US08937091B2

  公开（公告）日：2015-01-20

  The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein R1 is a substituted or unsubstituted aryl or heterocyclyl group, R2, R3, and R4 are hydrogen atoms, n is 2, X is halogen, R5 and R6 independently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein R5 and R6 are not hydrogen atoms at the same time, or R5 and R6 may be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

  本发明涉及具有转麦芽胺酰胺酶抑制活性的酮类化合物，其由以下式子1、2或3表示：其中R1是取代或未取代的芳基或杂环基，R2、R3和R4是氢原子，n为2，X为卤素，R5和R6分别表示氢原子或取代或未取代的C1-C10烷基、芳基或芳基烷基，其中R5和R6不能同时为氢原子，或R5和R6可以结合形成含有氮原子（N）的饱和或不饱和、取代或未取代的杂环基；一种蛋白交联抑制剂，包括该化合物；以及一种用于预防或治疗蛋白交联病因性疾病的组合物，其包括该化合物或蛋白交联抑制剂。
• Diastereoselective Radical 1,4-Ester Migration: Radical Cyclizations of Acyclic Esters with SmI₂
  作者：Charlotte Morrill、Áron Péter、Ilma Amalina、Emma Pye、Giacomo E. M. Crisenza、Nikolas Kaltsoyannis、David J. Procter

  DOI：10.1021/jacs.2c05972

  日期：2022.8.3

  Reductive cyclizations of carbonyl compounds, mediated by samarium(II) diiodide (SmI2, Kagan’s reagent), represent an invaluable platform to generate molecular complexity in a stereocontrolled manner. In addition to classical ketone and aldehyde substrates, recent advances in radical chemistry allow the cyclization of lactone and lactam-type substrates using SmI2. In contrast, acyclic esters are considered

  由二碘化钐（SmI 2，Kagan 试剂）介导的羰基化合物的还原环化代表了以立体控制方式产生分子复杂性的宝贵平台。除了经典的酮和醛底物外，自由基化学的最新进展允许使用 SmI 2环化内酯和内酰胺型底物。相比之下，无环酯被认为对 SmI 2不反应，并且它们参与还原环化是前所未有的。在这里，我们报告了由 SmI 2介导的非对映选择性自由基 1,4-酯迁移过程，它通过 α-碳甲氧基 δ-内酯中的无环酯基团的自由基环化提供立体定义的烯烃加氢羧化产物。同位素标记实验和计算研究已被用于探索迁移的机制。我们建议构象转换将单电子从 SmI 2转移到无环酯基团，而不是“更具反应性”的内酯羰基。我们的研究为在 SmI 2介导的还原环化中使用源自无环酯的难以捉摸的酮基自由基铺平了道路。
• Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-Pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus
  作者：Bruce D. Roth、D. F. Ortwine、M. L. Hoefle、C. D. Stratton、D. R. Sliskovic、M. W. Wilson、R. S. Newton

  DOI：10.1021/jm00163a005

  日期：1990.1

  A novel series of trans-6-(2-pyrrol-1-ylethyl)-4-hydroxypyran-2-ones and their dihydroxy acid derivatives were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase in vitro. A systematic study of substitution at the 2- and 5-positions of the pyrrole ring revealed that optimum potency was realized with the 2-(4-fluorophenyl)-5-isopropyl derivative 8x, which possessed 30% of the in vitro activity of the potent fungal metabolite compactin (I). A molecular modeling analysis led to the description of a pharmacophore model characterized by (A) length limits of 5.9 and 3.3 A for the 2- and 5-substituents, respectively, as well as an overall width limit of 10.6 A across the pyrrole ring from the 2- to the 5-substituent and (B) an orientation of the ethyl(ene) bridge to the 4-hydroxypyran-2-one ring nearly perpendicular to the planes of the parent pyrrole, hexahydronaphthalene, and phenyl rings of the structures examined (Figure 3, theta = 80-110 degrees). Attempts to more closely mimic compactin's polar isobutyric ester side chain with the synthesis of 2-phenylpyrroles containing polar phenyl substituents resulted in analogues with equal or slightly reduced potencies when compared to the 2-[(unsubstituted or 4-fluoro)phenyl]pyrroles, supporting the hypothesis that inhibitory potency is relatively insensitive to side-chain polarity or charge distribution in this area.